title: Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
abstract: Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B+C; N=65) vs. tamoxifen (A+D; N=55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores=0.28, P=0.04, 95% CI: 0.02, 0.54, Cohen's D=0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen.
authors.affiliation: Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, Victoria, Australia. Kelly.Phillips@petermac.org
authors.forename: Kelly-Anne
authors.initials: KA
authors.lastname: Phillips
authors.forename: Karin
authors.initials: K
authors.lastname: Ribi
authors.forename: Zhuoxin
authors.initials: Z
authors.lastname: Sun
authors.forename: Alisa
authors.initials: A
authors.lastname: Stephens
authors.forename: Alastair
authors.initials: A
authors.lastname: Thompson
authors.forename: Vernon
authors.initials: V
authors.lastname: Harvey
authors.forename: Beat
authors.initials: B
authors.lastname: Thürlimann
authors.forename: Fatima
authors.initials: F
authors.lastname: Cardoso
authors.forename: Olivia
authors.initials: O
authors.lastname: Pagani
authors.forename: Alan S
authors.initials: AS
authors.lastname: Coates
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: Karen N
authors.initials: KN
authors.lastname: Price
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
authors.forename: Jürg
authors.initials: J
authors.lastname: Bernhard
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D017024:Chemotherapy, Adjuvant; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D017698:Postmenopause; D018709:Statistics, Nonparametric; D013629:Tamoxifen / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole
references.citation: J Sleep Res. 2003 Dec;12(4):265-74
references.pmid: 14633237
references.citation: Br J Sports Med. 2001 Oct;35(5):297-302
references.pmid: 11579059
references.citation: Cancer. 2008 Nov 1;113(9):2431-9
references.pmid: 18823033
references.citation: Breast Cancer Res Treat. 2005 Aug;92(3):199-206
references.pmid: 16155790
references.citation: N Engl J Med. 2009 Aug 20;361(8):766-76
references.pmid: 19692688
references.citation: Neurosci Res. 2007 Jul;58(3):272-7
references.pmid: 17467093
references.citation: Ann Oncol. 1997 Sep;8(9):825-35
references.pmid: 9358933
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: Psychooncology. 2004 Jan;13(1):61-6
references.pmid: 14745746
references.citation: Endocr Rev. 2003 Apr;24(2):133-51
references.pmid: 12700177
references.citation: Cancer. 1999 Mar 1;85(5):1186-96
references.pmid: 10091805
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1294-300
references.pmid: 20142601
references.citation: Br J Clin Psychol. 1982 Feb;21(1):1-16
references.pmid: 7126941
references.citation: Neuroscience. 2008 Jan 2;151(1):186-94
references.pmid: 18061360
references.citation: Ann Neurol. 2003 May;53(5):607-15
references.pmid: 12730994
references.citation: Ann Oncol. 2008 Apr;19(4):623-9
references.pmid: 17974553
references.citation: Endocr Rev. 1995 Feb;16(1):35-62
references.pmid: 7758432
references.citation: Psychooncology. 2009 Aug;18(8):811-21
references.pmid: 19085975
references.citation: Support Care Cancer. 2006 Nov;14(11):1111-8
references.pmid: 16538498
references.citation: Hum Psychopharmacol. 2005 Jun;20(4):263-73
references.pmid: 15912482
references.citation: Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):269-76
references.pmid: 11812532
references.citation: Menopause. 2007 Nov-Dec;14(6):995-8
references.pmid: 17898668
references.citation: Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):119-28
references.pmid: 10581405
references.citation: Eur J Cancer. 2007 Jun;43(9):1342-7
references.pmid: 17499988
references.citation: Arch Clin Neuropsychol. 2009 Mar;24(2):165-78
references.pmid: 19395350
references.citation: JAMA. 2003 May 28;289(20):2663-72
references.pmid: 12771113
references.citation: J Natl Cancer Inst. 2003 Feb 5;95(3):190-7
references.pmid: 12569140
references.citation: Lancet Oncol. 2008 Oct;9(10):953-61
references.pmid: 18768369